Literature DB >> 6442439

beta-Phenylethylamine and reinforcement.

A J Greenshaw.   

Abstract

beta-Phenylethylamine is an endogenous brain amine which has been characterised as an endogenous amphetamine. The rewarding properties of the structurally similar drug amphetamine in humans and other species indicate a possible role for endogenous beta-phenylethylamine in neural processes underlying reward or reinforcement. Evidence for reinforcing properties of beta-phenylethylamine in the drug self-administration and place preference paradigms is briefly reviewed. The possibility that endogenous beta-phenylethylamine may be involved in reinforcement processes is also considered in relation to studies of intracranial self-stimulation. The contrasting aversive stimulus properties of beta-phenylethylamine and of amphetamine are described.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6442439     DOI: 10.1016/0278-5846(84)90023-x

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  4 in total

1.  Augmentation of methamphetamine-induced behaviors in transgenic mice lacking the trace amine-associated receptor 1.

Authors:  Cindy Achat-Mendes; Laurie J Lynch; Katherine A Sullivan; Eric J Vallender; Gregory M Miller
Journal:  Pharmacol Biochem Behav       Date:  2011-11-04       Impact factor: 3.533

Review 2.  Trace amine-associated receptor 1: A promising target for the treatment of psychostimulant addiction.

Authors:  Li Jing; Jun-Xu Li
Journal:  Eur J Pharmacol       Date:  2015-06-16       Impact factor: 4.432

3.  A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion.

Authors:  Debra S Harris; Thomas Everhart; Peyton Jacob; Emil Lin; John E Mendelson; Reese T Jones
Journal:  BMC Clin Pharmacol       Date:  2009-08-01

Review 4.  Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications.

Authors:  Yue Pei; Aman Asif-Malik; Juan J Canales
Journal:  Front Neurosci       Date:  2016-04-05       Impact factor: 4.677

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.